Abridge vs Heidi Health
The two run different maps. Abridge is the US enterprise reference standard: Best in KLAS for Ambient AI in 2025 and 2026, the category's largest peer reviewed study with 1,306 Kaiser Permanente clinicians in NEJM AI, native Epic depth, and Linked Evidence tracing every sentence of a note back to source audio. Heidi's claim is breadth: a reported 2.5 million consults a week across 110 languages, 190 countries, and more than 200 specialties, with published pricing from a free tier and a product expanding into cited decision support through Heidi Evidence. The procurement catch sits on Heidi's side: an organization wide Business Associate Agreement and push to chart integration are both reported as gated to upper tiers, so a US buyer should evaluate the tier they would actually sign. If your failure mode is auditable evidence and structured Epic workflow in a US health system, start with Abridge. If your failure mode is languages, geographies, or needing a price without a sales call, start with Heidi.
- The evidence gap is the widest in this pairing: Abridge holds the category's largest independent peer reviewed study and consecutive Best in KLAS awards, while Heidi's clinical evidence grades C with no accuracy study against ground truth retrieved.
- Structured workflow, not copy and paste: native embedding across Epic Haiku, Canto, and Hyperdrive with bidirectional sync, extending into structured orders and real time prior authorization, where Heidi's push to chart is reported as gated to the Practice tier upward.
- Compliance posture is unconditional: Linked Evidence gives sentence level verification before signing, and no BAA tier gates apply, against Heidi's C grade on the HIPAA axis for gating the organization wide BAA to upper tiers.
- Language and geography decide it: a reported 110 languages across 190 countries and more than 200 specialties, the broadest coverage in the category, against Abridge's stated 28 plus languages and US enterprise center of gravity.
- You need a price without a sales call: a free tier with unlimited transcription and a published Clinician tier at $150 per user per month billed annually, where Abridge publishes nothing and offers no individual plan.
- The platform is expanding under you: Heidi Evidence surfaces cited clinical decision support from BMJ, NICE, and HealthPathways at the point of care, and Heidi Comms coordinates patient calls, on a company that raised a $65 million Series B in late 2025.
Side-by-Side
| Axis | A Abridge |
H Heidi Health |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | — | |
| Model and Technology Transparency | — | — |
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | — | — |
| HIPAA and BAA Posture | — | |
| Security Certifications and Trust Center | — | |
| FDA and Regulatory Status | — | — |
| AI Governance and Bias Disclosure | — | — |
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | — | — |
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Volume figures for both vendors are vendor published, including Heidi's 2.5 million weekly consults and Abridge's 250 plus health systems; Abridge's evidence grade reflects the scale and venue of the Kaiser Permanente study rather than a re verification of its findings. Heidi's clinical evidence grades C on this index, and third party review is unusually candid about limits, including that multi problem visits document less reliably than single problem encounters. Two Heidi tier gates matter for US buyers: the organization wide BAA and EHR write back are both reported as available only from the Practice tier upward; confirm coverage on the contracted tier before deployment. Heidi's pricing was restructured in February 2026 and sources conflict on some tier amounts. Abridge publishes no pricing; a third party estimate near $2,500 per clinician per year is recorded as an estimate.